摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl 4-methoxy-12-amino>-11-oxo-2-azatricyclo<12.2.2.13,7>nonadeca-3,5,7(19),14,16,17-hexaene-9-carboxylate | 138571-37-6

中文名称
——
中文别名
——
英文名称
methyl 4-methoxy-12-amino>-11-oxo-2-azatricyclo<12.2.2.13,7>nonadeca-3,5,7(19),14,16,17-hexaene-9-carboxylate
英文别名
methyl 12(S)--4-methoxy-11-oxo-10-aza-2-oxatricyclo<12.2.2.13,7>-nonadeca-3,5,7(19),14,16,17-hexaene-9(R)-carboxylate;methyl (9S,12S)-4-methoxy-12-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]-11-oxo-2-oxa-10-azatricyclo[12.2.2.13,7]nonadeca-1(16),3,5,7(19),14,17-hexaene-9-carboxylate
methyl 4-methoxy-12-<N-methyl-N-<(1,1-dimethylethoxy)carbonyl>amino>-11-oxo-2-azatricyclo<12.2.2.1<sup>3,7</sup>>nonadeca-3,5,7(19),14,16,17-hexaene-9-carboxylate化学式
CAS
138571-37-6
化学式
C26H32N2O7
mdl
——
分子量
484.549
InChiKey
AFIVBHWCNCTPQG-PMACEKPBSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.9
  • 重原子数:
    35
  • 可旋转键数:
    6
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    103
  • 氢给体数:
    1
  • 氢受体数:
    7

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    methyl 4-methoxy-12-amino>-11-oxo-2-azatricyclo<12.2.2.13,7>nonadeca-3,5,7(19),14,16,17-hexaene-9-carboxylate盐酸 作用下, 以 四氢呋喃乙酸乙酯 为溶剂, 反应 12.5h, 生成 BOC-D-alanyl-L-alanyl-O4-methyl-L-tyrosyl-L-alanyl-N-methyl-L-tyrosyl-O4-methyl-L-tyrosine cyclic 54<*>63 ether, methyl ester
    参考文献:
    名称:
    N-Desmethyl Derivatives of Deoxybouvardin and RA-VII: Synthesis and Evaluation
    摘要:
    The synthesis of the complete set of seven N-desmethyl derivatives of RA-VII (8) are described. Thus, the synthesis of the four 14-membered cycloisodityrosine derivatives 21-24 and their coupling with the two tetrapeptides 32 and 33 followed by formation of the 18-membered ring with macrocyclization provided the full set of seven desmethyl derivatives 14-20 of RA-VII (8). The solution phase conformational properties of 8 and 14-20 were examined by 1D and 2D H-1 NMR to reveal the role of N-methylation on the key conformational aspects of the natural agents. In contrast to each of the simple cycloisodityrosine derivatives 21-24 which adopt a single, rigid solution conformation possessing a secondary or tertiary trans amide central to the 14-membered ring, the natural agents including 8 adopt a single predominant solution conformation (83-88%) that corresponds closely to the X-ray structure conformation which possesses an inherently disfavored cis C-30-N-29 tertiary amide central to the 14-membered cycloisodityrosine subunit. Moreover, this cis amide is the predominant conformation (85-95%) observed with N-29-desmethyl RA-VII (14) indicating that even a secondary C-30-N-29 amide adopts this inherently disfavored cis amide stereochemistry. The minor conformation of 8 observed in solution (12-17%) is shown to be derived from a minor cis C-8-N-9 tertiary amide which was not observed with its conversion to a secondary amide. Both N-9-desmethyl RA-VII (15) and N-9,N-29-desmethyl RA-VII (18) adopt exclusively a single solution conformation that corresponds to the major solution conformations of 8 and 14. This conformation contains a characteristic cis C-30-N-29 amide central to a type VI beta-turn and the cycloisodityrosine subunit, a trans C-8-N-9 amide central to a typical type II beta-turn capped with a tight Ala(4)-NH-O=C-Ala(1) hydrogen bond, and a trans C-14-N-15 N-methyl amide. In sharp contrast, removal of the N-15 methyl group within 16, 17, 19, and 20 results in the adoption of solution conformations possessing the inherently favored trans C-30-N-29 amide central to the cycloisodityrosine (14)-membered subunit. Thus, the N-15-methyl group within 8 is responsible for the agents adoption of the disfavored cis C-30-N-29 amide central to the cycloisodityrosine subunit. Importantly, preceding studies have defined the cycloisodityrosine subunit of 8 as the pharmacophore and, in a reversal of the initially assigned roles, revealed that it is the tetrapeptide housed in the 18-membered ring that induces and maintains the rigid, normally inaccessible cis C-30-N-29 amide conformation within the 14-membered cycloisodityrosine subunit. The studies detailed herein reveal that it is the N-15-methyl group that induces this conformational preference for the disfavored cis C-30-N-29 amide and that its removal results in a major conformational change with adoption of the trans C-30-N-29 amide and a loss of biological activity.Thus, the N-15-methyl group is essential for maintenance of the conformational and biological properties of 8; the N-9-methyl group is not essential, and its removal leads to exclusive population of a single biologically active conformation; and the N-29-methyl group once thought essential td the adoption of the C-30-N-29 cis amide is not essential, and its removal does not alter the conformational or biological properties of 8.
    DOI:
    10.1021/ja00133a010
  • 作为产物:
    参考文献:
    名称:
    环异二酪氨酸、RA-VII、脱氧布瓦丁和 N29-去甲基-RA-VII 的全合成:药效团的鉴定和亚基功能作用的逆转
    摘要:
    基于有效的分子内 Ullmann 反应作为制备难以捉摸的 14 元环异二酪氨酸亚基 (33) 的关键大环化反应的实施,描述了 RA-VII (1) 和脱氧布瓦丁 (2) 的简明全合成的全部细节的双环六肽。随后 34 与四肽 17 偶联以及大环化与 C 2 -N 3 酰胺键形成提供了 1 和 2。在解决有助于其抗肿瘤活性的药物的关键结构和构象特征的努力中,N 29 -去甲基-RA-制备了 VII 并详细说明了其化学、构象和初步生物学特性
    DOI:
    10.1021/ja00062a004
点击查看最新优质反应信息

文献信息

  • Synthesis of (9<i>R</i>,12<i>S</i>)- and (9<i>S</i>,12<i>S</i>)-Cycloisodityrosine and Their <i>N</i>-Methyl Derivatives
    作者:Dale L. Boger、Jiacheng Zhou、Robert M. Borzilleri、Seiji Nukui、Steven L. Castle
    DOI:10.1021/jo961346o
    日期:1997.4.1
    Full details of the synthesis of (9R,12S)- and (9S,12S)-cycloisodityrosine and their N-methyl derivatives are detailed based on an intramolecular nucleophilic aromatic substitution reaction for formation of the key biaryl ether with 14-membered ring macrocyclization. Their comparison with prior samples and the documentation of a facile C9 epimerization within the natural 9S series are described.
    基于分子内亲核芳族取代反应以形成具有14元环大环化的关键联芳基醚,详细描述了(9R,12S)-和(9S,12S)-环异酪氨酸及其N-甲基衍生物的合成的详细信息。描述了它们与先前样品的比较以及天然9S系列中C9差向异构酶的简便记录。
  • Synthesis of N29-desmethyl RA-VII. Identification of the pharmacophore of RA-I-VII and deoxybouvardin and reassignment of the subunit functional roles
    作者:Dale L. Boger、Daniel Yohannes、James B. Myers
    DOI:10.1021/jo00031a001
    日期:1992.2
    N29-Desmethyl RA-VII was prepared in efforts that address the key structural and conformational features of the agent that contribute to its antitumor activity.
  • N-Desmethyl Derivatives of Deoxybouvardin and RA-VII: Synthesis and Evaluation
    作者:Dale L. Boger、Jiacheng Zhou
    DOI:10.1021/ja00133a010
    日期:1995.7
    The synthesis of the complete set of seven N-desmethyl derivatives of RA-VII (8) are described. Thus, the synthesis of the four 14-membered cycloisodityrosine derivatives 21-24 and their coupling with the two tetrapeptides 32 and 33 followed by formation of the 18-membered ring with macrocyclization provided the full set of seven desmethyl derivatives 14-20 of RA-VII (8). The solution phase conformational properties of 8 and 14-20 were examined by 1D and 2D H-1 NMR to reveal the role of N-methylation on the key conformational aspects of the natural agents. In contrast to each of the simple cycloisodityrosine derivatives 21-24 which adopt a single, rigid solution conformation possessing a secondary or tertiary trans amide central to the 14-membered ring, the natural agents including 8 adopt a single predominant solution conformation (83-88%) that corresponds closely to the X-ray structure conformation which possesses an inherently disfavored cis C-30-N-29 tertiary amide central to the 14-membered cycloisodityrosine subunit. Moreover, this cis amide is the predominant conformation (85-95%) observed with N-29-desmethyl RA-VII (14) indicating that even a secondary C-30-N-29 amide adopts this inherently disfavored cis amide stereochemistry. The minor conformation of 8 observed in solution (12-17%) is shown to be derived from a minor cis C-8-N-9 tertiary amide which was not observed with its conversion to a secondary amide. Both N-9-desmethyl RA-VII (15) and N-9,N-29-desmethyl RA-VII (18) adopt exclusively a single solution conformation that corresponds to the major solution conformations of 8 and 14. This conformation contains a characteristic cis C-30-N-29 amide central to a type VI beta-turn and the cycloisodityrosine subunit, a trans C-8-N-9 amide central to a typical type II beta-turn capped with a tight Ala(4)-NH-O=C-Ala(1) hydrogen bond, and a trans C-14-N-15 N-methyl amide. In sharp contrast, removal of the N-15 methyl group within 16, 17, 19, and 20 results in the adoption of solution conformations possessing the inherently favored trans C-30-N-29 amide central to the cycloisodityrosine (14)-membered subunit. Thus, the N-15-methyl group within 8 is responsible for the agents adoption of the disfavored cis C-30-N-29 amide central to the cycloisodityrosine subunit. Importantly, preceding studies have defined the cycloisodityrosine subunit of 8 as the pharmacophore and, in a reversal of the initially assigned roles, revealed that it is the tetrapeptide housed in the 18-membered ring that induces and maintains the rigid, normally inaccessible cis C-30-N-29 amide conformation within the 14-membered cycloisodityrosine subunit. The studies detailed herein reveal that it is the N-15-methyl group that induces this conformational preference for the disfavored cis C-30-N-29 amide and that its removal results in a major conformational change with adoption of the trans C-30-N-29 amide and a loss of biological activity.Thus, the N-15-methyl group is essential for maintenance of the conformational and biological properties of 8; the N-9-methyl group is not essential, and its removal leads to exclusive population of a single biologically active conformation; and the N-29-methyl group once thought essential td the adoption of the C-30-N-29 cis amide is not essential, and its removal does not alter the conformational or biological properties of 8.
  • Total synthesis of cycloisodityrosine, RA-VII, deoxybouvardin, and N29-desmethyl-RA-VII: Identification of the pharmacophore and reversal of the subunit functional roles
    作者:Dale L. Boger、Daniel Yohannes、Jiacheng Zhou、Michael A. Patane
    DOI:10.1021/ja00062a004
    日期:1993.5
    Full details of a concise total synthesis of RA-VII (1) and deoxybouvardin (2) are described based on the implementation of an effective intramolecular Ullmann reaction as the key macrocyclization reaction in the preparation of the elusive 14-membered cycloisodityrosine subunit (33) of the bicyclic hexapeptides. Subsequent coupling of 34 to tetrapeptide 17 and macrocyclization with C 2 -N 3 amide bond
    基于有效的分子内 Ullmann 反应作为制备难以捉摸的 14 元环异二酪氨酸亚基 (33) 的关键大环化反应的实施,描述了 RA-VII (1) 和脱氧布瓦丁 (2) 的简明全合成的全部细节的双环六肽。随后 34 与四肽 17 偶联以及大环化与 C 2 -N 3 酰胺键形成提供了 1 和 2。在解决有助于其抗肿瘤活性的药物的关键结构和构象特征的努力中,N 29 -去甲基-RA-制备了 VII 并详细说明了其化学、构象和初步生物学特性
查看更多